Piper Sandler Initiates Coverage of National Energy Services Reunited (NESR) Stock With an Overweight Rating
A drilling rig in action, operated by an oilfield services team.
Despite the global economic headwinds, National Energy Services Reunited Corp. (NASDAQ:NESR) believes that conditions in the MENA region are supportive of growth, and it is focused on core strategic priorities. These include reporting profitable revenue growth, enhancing execution efficiency, commercializing new technology, as well as improving debt reduction and working capital efficiency to help long-term financial performance.
National Energy Services Reunited Corp. (NASDAQ:NESR)'s net debt to adjusted EBITDA ratio was below 1.0, ending Q1 2025 at 0.93 as of March 31, 2025. This reflects a significant improvement from 1.30 as of March 31, 2024.
National Energy Services Reunited Corp. (NASDAQ:NESR) is one of the leading national oilfield services providers.
While we acknowledge the potential of NESR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Briumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide
TG Therapeutics Inc. (NASDAQ:TGTX) stock is trading lower on Monday after the company reported worse-than-expected second-quarter 2025 earnings. What Happened TG Therapeutics reported second-quarter earnings per share of 17 cents, up from 4 cents a year ago, but below the consensus of 19 cents. The multiple sclerosis-focused company reported sales of $141.15 million, up from $73.5 million a year ago, missing the consensus of $146.42 the second quarter of 2025, Briumvi's U.S. net product revenue surged to $138.8 million, marking a significant 91% increase year-over-year and a 16% rise from the previous quarter. The drug's commercialization is also expanding globally with the company's partner, Neuraxpharm, with Briumvi now approved in the European Union, the United Kingdom, Switzerland, and Australia. Cash, cash equivalents and investment securities were $278.9 million as of June 30, 2025. TG Therapeutics anticipates that cash, cash equivalents, and investment securities as of June 30, 2025, combined with the projected revenues from Briumvi, will be sufficient to fund the business based on the current operating plan. Pipeline Development Patient enrollment was commenced in the randomized Phase 3 pivotal program to evaluate a consolidated Day 1 and Day 15 dosing regimen for IV Briumvi in the ongoing ENHANCE trial. View more earnings on TGTX The company has dosed the first patient with progressive multiple sclerosis in the Phase 1 clinical trial evaluating azer-cel for the treatment of autoimmune diseases. Guidance 'The strong uptake we're seeing, combined with deepening physician confidence and compelling patient experiences, underscores the strength of our launch strategy and gives us confidence in reaching our updated 2025 full year BRIUMVI U.S. net revenue guidance of $570 to $575 million,' said Michael Weiss, Chairman and CEO. TG Therapeutics raised its 2025 revenue outlook for Briumvi to a range of $570 million to $575 million, up from its previous guidance of $560 million. However, this is still below the consensus estimate of $596.12 million. TG Therapeutics raised fiscal 2025 Briumvi's U.S. net product revenue target to $570 million-$575 million from $560 million in prior guidance versus consensus estimate of $596.12 million. The company raised total global revenue target to approximately $585 million for the full year 2025 (prior guidance of $575 million for full year 2025). Price Action: TGTX stock is trading lower by 14.6% to $29.91 at last check Monday. Read Next:Photo by Piotr Swat via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Briumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
a minute ago
- Yahoo
TSLA: Tesla Approves $29 Billion For Musk Amid Falling Sales, Legal Chaos
Aug 4 - Tesla (NASDAQ:TSLA) is not shy about betting big on Elon Musk. The company just approved a fresh 96 million-share compensation package for its CEO, worth around $29 billion. It's all about keeping Musk locked in, especially after a Delaware court tossed out his original $50 billion pay deal from 2018, calling it unfair to shareholders. Now, Musk is fighting that ruling in court. But in the meantime, Tesla's board put together a new plan. The shares won't vest unless Musk stays in a top executive role through 2027, and even then, they come with a five-year holding period. Tesla also says there won't be any double-dipping if his old package gets reinstated. All this is happening while Tesla faces real challenges. Sales are down, the Cybertruck hasn't delivered, and competition from legacy automakers like General Motors (NYSE:GM), Hyundai (HYMTF), and BMW (BMWYY) is heating up. On top of that, Musk's political moves haven't helped Tesla's brand loyalty. Still, this new award could help steady the ship, at least if Musk sticks around. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
Can Super Micro's AI Demand Outpace Profit Margin Fears?
Super Micro Computer (NASDAQ:SMCI) is navigating a complex market landscape as it prepares to report its fiscal fourth-quarter earnings with a significant long-term growth narrative in the AI server space tempered by immediate concerns about market visibility and sustained pressure on profit margins. The company's heavy reliance on key suppliers and a competitive environment, where large-scale deals and component costs weigh on profitability, creates a cautious outlook despite its strong position as a leading beneficiary of rising AI infrastructure spending. Analyst Matt Bryson of Wedbush, in a note released on Monday, reiterated a Neutral rating on Super Micro with a $30 price forecast ahead of the company's earnings report scheduled for August the analyst acknowledged Super Micro's positioning as a key beneficiary of accelerating AI infrastructure spend, particularly in the server market, he expressed caution over near-term visibility and uncertainty around actual demand strength. Bryson noted that Super Micro stands to benefit from secular trends that align with its core strengths. Spending from neocloud providers, AI model builders, and sovereign buyers continues to grow, and these customers are increasingly turning to OEMs like Super Micro and Dell Technologies (NYSE:DELL) to meet their AI server requirements. He added that Nvidia's (NASDAQ:NVDA) apparent prioritization of GB200 deliveries to OEMs, rather than directly to hyperscalers, could serve as a tailwind for Super Micro. Peer company Gigabyte, for example, recently reported a 50% quarter-over-quarter sales surge, a result Bryson attributed to increased AI server shipments. If current market dynamics hold, Bryson sees a long-term path for Super Micro to potentially reach $10 billion in quarterly sales, echoing targets previously laid out by Super Micro CEO Charles Liang. This would be a significant leap from the $5.9 billion revenue consensus for fiscal fourth quarter and the $6.4 billion projection for calendar first quarter. However, Bryson underscored that visibility into Super Micro's actual build and demand trends remains limited. The company's heavy reliance on related parties for component sourcing and manufacturing complicates tracking real-time activity. Additionally, data from third-party sources has yet to reflect the level of demand surge expected from recent AI server trends. While strength in Taiwan-based suppliers like Wistron suggests a robust upstream environment, Bryson's team has not been able to confirm that Super Micro is directly seeing similar momentum in its own sales funnel. Margins also remain a key concern. Gross margins are expected to stay under pressure in the near term due to an increasing share of Nvidia (NASDAQ:NVDA) content in Super Micro's bill of materials. According to conversations with ODMs and OEMs, GB200-based designs leave little room for differentiation, further compressing vendor margins. Management has guided fiscal fourth-quarter gross margins to remain around 10%, roughly in line with the 9.7% margin reported in the previous quarter. The analyst characterized this conservatism as prudent, citing the lower-margin profile of large-scale deals, rising Nvidia component costs, and a lack of meaningful relief in memory pricing. For the fiscal fourth quarter, Super Micro management projected revenue in the range of $5.6 billion to $6.4 billion and adjusted earnings per share between 40 cents and 50 cents. Operating expenses are expected to reach $245 million, with an adjusted tax rate of 16.5%. The fully diluted share count is projected at 642 million, and capital expenditures are guided between $45 million and $55 million. Despite Super Micro's significant share price appreciation over the past few months, Bryson remains on the sidelines. Price Action: SMCI shares were trading higher by 3.88% to $58.84 at last check Monday. Image via Shutterstock Latest Ratings for SMCI Date Firm Action From To May 2021 Susquehanna Maintains Positive May 2021 Northland Capital Markets Maintains Outperform Jun 2020 Northland Capital Markets Initiates Coverage On Outperform View More Analyst Ratings for SMCI View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? SUPER MICRO COMPUTER (SMCI): Free Stock Analysis Report This article Can Super Micro's AI Demand Outpace Profit Margin Fears? originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
